Case Report
Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy

Sandy El Bitar, Chanudi Weerasinghe, Elie El-Charabaty, and Marcel Odaimi

1Department of Internal Medicine, Northwell Health Staten Island University Hospital, Staten Island, NY, USA
2Department of Hematology and Oncology, Northwell Health Staten Island University Hospital, Staten Island, NY, USA
3Department of Nephrology, Northwell Health Staten Island University Hospital, Staten Island, NY, USA

Correspondence should be addressed to Sandy El Bitar; sandybitar87@gmail.com

Received 26 October 2017; Accepted 18 January 2018; Published 31 January 2018

Academic Editor: Raffaele Palmirotta

Copyright © 2018 Sandy El Bitar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Immune checkpoint blockade therapy is gaining popularity among oncologists for treatment of solid and hematologic malignancies. The widespread use of these agents resulted in increasing incidence of renal immune-related adverse events. Reported renal toxicity described so far includes acute interstitial nephritis, minimal change disease, and immune complex glomerulonephritis. We report the case of a 79-year-old female with metastatic non-small cell lung cancer on anti-PD-1 therapy nivolumab. After the 4th administration of nivolumab, the treatment course was complicated with normal anion gap metabolic acidosis. Urine and blood studies were in favor of distal renal tubular acidosis (RTA). Following a negative workup for an underlying etiology, immunotherapy-induced RTA was suspected. Withholding of the offending agent and initiation of steroid therapy resulted in adequate response. The present report provides the first presentation of RTA as a renal immune-related adverse event secondary to nivolumab. Nephrologists and oncologists should be familiar with potentially life-threatening renal side effects induced by immune checkpoint inhibitors.

1. Introduction

Novel therapeutic agents targeting PD-1 signaling are increasing in popularity among oncologists. Pembrolizumab and nivolumab have been approved by the US Food and Drug Administration for treatment of several malignancies and are showing high rates of durable clinical responses [1]. However, due to their immunologic effects, there have been a number of reported toxicities termed as immune-related adverse events (irAEs), classified and graded by the National Cancer Institute clinical terminology criteria of adverse events (CTCAE).

Renal adverse events are uncommon, with the highest rate reported in a phase II lung cancer trial at 4% [2, 3]. Three different forms of renal irAE have been described so far: acute interstitial nephritis, minimal change disease, and immune complex glomerulonephritis [4–7]. All three forms manifest as acute kidney injury (AKI) and rise in serum creatinine.

In this report, we present a case of nivolumab-induced renal tubular acidosis successfully treated with steroids and sodium bicarbonate.

2. Case Presentation

A 79-year-old woman with past medical history of stage IV non-small cell lung cancer (NSCLC), heart failure with preserved ejection fraction, and dyslipidemia presented to the emergency department with generalized weakness and fatigue. Patient was initiated on nivolumab 3 months prior to presentation as a second line treatment following failure of chemotherapy with carboplatin and pemetrexed, confirmed by progressive disease on PET/CT scan. Home medications included rosuvastatin, docusate sodium, and low-dose furosemide. Patient received nivolumab 240 mg every 2 weeks. Following her fourth dose, she started complaining of worsening generalized fatigue and progressive weakness. Upon outpatient evaluation, her creatinine was found to be
are increasing with the introduction of immunotherapy. The incidence and nature of renal irAEs in oncology is a concern.

### 3. Discussion

The incidence and nature of renal irAEs in oncology are increasing with the introduction of immunotherapy. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are two important immune checkpoint receptors expressed by T lymphocytes and targeted by the new therapies. CTLA-4 plays a critical role in the early immune response occurring in lymphoid tissues. As T-cell receptors (TCR) bind antigen/MHC on antigen-presenting cells (APC), the coinhibitory receptor CTLA-4 is overexpressed in many cancers is activated, leading to the inhibition of memory T-cell function. Following the priming and activation of T-cell lymphocytes, the coinhibitory PD-1 receptor expressed by T-cells of peripheral tissue binds to their ligands on cancerous cells (PD-L1 and PD-L2). This association results in T-cell anergy and decrease in cytokine release, hence suppressing the antitumor response [8, 9]. Nivolumab is a new PD-1 antibody with antitumor activity. It binds to PD-1 receptor and blocks its inhibitory pathway, hence stimulating lymphocyte cells to target tumor cells. It is now being used for treatment of non-small lung cancer, metastatic melanoma, renal cell carcinoma, squamous cell carcinoma of the head and neck, and classical Hodgkin lymphoma, as first or second line treatment [1, 2]. Studies have shown response rates as high as 40% in patients with solid tumors [2, 3]. In advanced NSCLC, response rate can reach up to 20% [2]. Nevertheless, these high numbers happen at the expense of several adverse effects. On a physiological level, immune checkpoint inhibitory pathways suppress immune response against self-antigens. Targeting these regulators may enhance an inflammatory response of normal tissue, resulting in immune invasion and damage [9]. The most common toxicities included cutaneous, gastrointestinal, hepatic, endocrine, and renal side effects. Hofmann et al. conducted a retrospective chart review study for reported adverse events of pembrolizumab and nivolumab noting renal involvement in only 1-2% of reported irAEs [10].

Three different forms of renal AE have been reported so far: acute tubulointerstitial nephritis (ATIN), immune complex GN, and minimal change disease [4–7]. Irrespective of the underlying mechanism of irAEs, most respond well to steroid therapy. Based on the data derived from case series and case reports, treatment with glucocorticoids resulted in an excellent overall prognosis [10].

In our patient, the AKI was believed to be prerenal, considering the calculated FeNa was below 1% and the adequate response to intravenous fluids. However, the worsening acidosis despite improved renal function was suggestive of RTA. Extensive workup for an underlying etiology was negative, suggesting a drug-induced RTA secondary to nivolumab. Despite the elevated titer of ANA, it remains nonspecific as the rest of the autoimmune panel was negative. The alkaline urine PH despite significantly low serum bicarbonate and the adequate response to relatively low alkali supplementation was more in favor of a distal RTA. The underlying mechanism for autoimmune distal RTA is secondary to distal tubule proton pump defect from immunologic injury or autoantibodies [11]. Bearing in mind the importance of PD-1 signaling in minimizing the T-cell-mediated renal inflammation [10], anti-PD-1 agents are likely to induce immunologic injuries similar to that seen in autoimmune diseases resulting in RTA.
Establishing a relation between a certain drug and a side effect can be challenging, especially when a patient is exposed to multiple nephrotoxic drugs. In our case, the patient received maintenance pemetrexed, an antifolate drug, for 8 cycles. During the treatment period and 3 months after discontinuation of pemetrexed, her kidney function remained intact. Moreover, the association in time between administering nivolumab and the development of RTA, followed by normalization after administration of corticosteroids, is in favor of nivolumab-induced RTA.

Increase in use of immune checkpoint inhibitors should warrant attention to adverse side effects, mainly renal complications. To our knowledge, our case is the first to describe nivolumab-induced renal AEs manifesting as RTA. Early detection and initiation of steroid therapy/bicarbonate replacement can result in favorable outcomes. Renal monitoring for patients on anti-PD-1 agents is vital for early management of irAEs and prevention of severe renal damage.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

[1] S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer,” New England Journal of Medicine, vol. 366, no. 26, pp. 2443–2454, 2012.
[2] H. Borghaei, L. Paz-Ares, L. Horn et al., “Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer,” New England Journal of Medicine, vol. 373, no. 17, pp. 1627–1639, 2015.
[3] N. A. Rizvi, J. Mazieres, D. Planchard et al., “Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial,” Lancet Oncology, vol. 16, no. 3, pp. 257–265, 2015.
[4] K. Jung, X. Zeng, and M. Bilusic, “Nivolumab-associated acute glomerulonephritis: a case report and literature review,” BMC Nephrology, vol. 17, no. 1, p. 188, 2016.
[5] N. Murakami, T. J. Borges, M. Yamashita, and L. V. Riella, “Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma,” Clinical Kidney Journal, vol. 9, no. 3, pp. 411–417, 2016.
[6] J. W. Vandiver, Z. Singer, and C. Harshberger, “Severe hyponatremia and immune nephritis following an initial infusion of nivolumab,” Targeted Oncology, vol. 11, no. 4, pp. 553–556, 2016.
[7] A. Bickel, I. Koneth, A. Enzler-Tschudy, J. Neuwiler, L. Flatz, and M. Fruh, “Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma,” BMC Cancer, vol. 16, no. 1, p. 656, 2016.
[8] A. Ribas, “Tumor immunotherapy directed at PD-1,” New England Journal of Medicine, vol. 366, no. 26, pp. 2517–2519, 2012.
[9] N. M. La-Beck, G. W. Jean, C. Huynh, S. K. Alzghari, and D. B. Lowe, “Immune checkpoint inhibitors: new insights and current place in cancer therapy,” Pharmacotherapy, vol. 35, no. 10, pp. 963–976, 2015.
[10] L. Hofmann, A. Forschner, C. Loquai et al., “Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy,” European Journal of Cancer, vol. 60, pp. 190–209, 2016.
[11] E. P. Cohen, B. Bastani, M. R. Cohen, S. Kolner, P. Hemken, and S. L. Gluck, “Absence of H(+)-ATPase in cortical collecting tubules of a patient with Sjogren’s syndrome and distal renal tubular acidosis,” Journal of American Society of Nephrology, vol. 3, no. 2, pp. 264–271, 1992.